Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study MPX111381: A Dose-ranging Study Evaluating the Efficacy, Safety and Tolerability of GSK1838262 (XP13512) in the Prophylactic Treatment of Migraine Headache

NCT00742209 is registered in ClinicalTrials.gov with XenoPort, Inc. as lead sponsor.

NCT NCT00742209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00742209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study MPX111381: A Dose-ranging Study Evaluating the Efficacy, Safety and Tolerability of GSK1838262 (XP13512) in the Prophylactic Treatment of Migraine Headache
Lead sponsor
XenoPort, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2008
Completion date
June 30, 2010
Enrollment
526 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

migraine, migraine disorders